Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients.
Humans
Melanoma
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
/ methods
Skin Neoplasms
/ diagnostic imaging
Fluorodeoxyglucose F18
Cohort Studies
Retrospective Studies
Radiopharmaceuticals
Neoplasm Staging
Neoplasm Recurrence, Local
/ pathology
Positron-Emission Tomography
/ methods
Melanoma, Cutaneous Malignant
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
31
08
2022
accepted:
12
12
2022
pubmed:
9
2
2023
medline:
23
3
2023
entrez:
8
2
2023
Statut:
ppublish
Résumé
The effect of routine imaging in melanoma surveillance is unknown. In 2016, Denmark was the first country in the world to implement routine imaging with positron emission tomography-computed tomography with fluorodeoxyglucose (FDG PET-CT) in a nationwide, population-based surveillance program. This study aimed to determine the impact of surveillance with routine FDG PET-CT on hazard, cumulative incidence, and absolute risk of overall, locoregional, and distant recurrence detection in patients with stage IIB to IIID cutaneous melanoma. This retrospective, population-based, nationwide cohort study used prospectively collected data from five national health registries to compare hazard, cumulative incidence, and absolute risk of recurrence in patients with cutaneous melanoma diagnosed in 2008-2010 (cohort 1, followed with clinical examinations) and patients with cutaneous melanoma diagnosed in 2016-2017 (cohort 2, followed with clinical examinations and routine FDG PET-CT at 6, 12, 24, and 36 months). The study included 1480 patients with stage IIB to IIID cutaneous melanoma. Cumulative incidences of overall and distant recurrence were higher in cohort 2, with a peak difference at three years (32.3 % vs 27.5 % and 25.8 % vs. 18.5 %, respectively). The hazard of recurrence was higher in cohort 2 during the first two years, with hazard rates for overall and distant recurrence of 1.16 (95 % confidence interval [CI], 0.93-1.44) and 1.51 (95 % CI, 1.16-1.96), respectively. The patterns persisted in absolute risk estimates. Patients with stage IIB to IIID melanoma followed with routine FDG PET-CT had a 51 % increased hazard of distant recurrence detection within the first two years of surveillance. Future studies must determine whether this earlier recurrence detection translates into improved survival.
Sections du résumé
BACKGROUND
BACKGROUND
The effect of routine imaging in melanoma surveillance is unknown. In 2016, Denmark was the first country in the world to implement routine imaging with positron emission tomography-computed tomography with fluorodeoxyglucose (FDG PET-CT) in a nationwide, population-based surveillance program. This study aimed to determine the impact of surveillance with routine FDG PET-CT on hazard, cumulative incidence, and absolute risk of overall, locoregional, and distant recurrence detection in patients with stage IIB to IIID cutaneous melanoma.
METHODS
METHODS
This retrospective, population-based, nationwide cohort study used prospectively collected data from five national health registries to compare hazard, cumulative incidence, and absolute risk of recurrence in patients with cutaneous melanoma diagnosed in 2008-2010 (cohort 1, followed with clinical examinations) and patients with cutaneous melanoma diagnosed in 2016-2017 (cohort 2, followed with clinical examinations and routine FDG PET-CT at 6, 12, 24, and 36 months).
RESULTS
RESULTS
The study included 1480 patients with stage IIB to IIID cutaneous melanoma. Cumulative incidences of overall and distant recurrence were higher in cohort 2, with a peak difference at three years (32.3 % vs 27.5 % and 25.8 % vs. 18.5 %, respectively). The hazard of recurrence was higher in cohort 2 during the first two years, with hazard rates for overall and distant recurrence of 1.16 (95 % confidence interval [CI], 0.93-1.44) and 1.51 (95 % CI, 1.16-1.96), respectively. The patterns persisted in absolute risk estimates.
CONCLUSIONS
CONCLUSIONS
Patients with stage IIB to IIID melanoma followed with routine FDG PET-CT had a 51 % increased hazard of distant recurrence detection within the first two years of surveillance. Future studies must determine whether this earlier recurrence detection translates into improved survival.
Identifiants
pubmed: 36752970
doi: 10.1245/s10434-022-13034-6
pii: 10.1245/s10434-022-13034-6
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2377-2388Subventions
Organisme : Kræftens Bekæmpelse
ID : R175-A11366
Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Barbour A, Guminski A, Liu W, Menzies S, Morton R, Cancer Council Australia Melanoma Guidelines Working Party. Follow-up After Initial Definitive Treatment for Each Stage of Melanoma–Cancer Guidelines Wiki, 2018. Retrieved 8 March 2022 at https://wiki.cancer.org.au/australiawiki/index.php?oldid=190154 .
National Comprehensive Cancer Network. NCCN Guidelines Version 2.2022. Melanoma: Cutaneous, 2022.
Pflugfelder A, Kochs C, Blum A, et al. Malignant melanoma S3-guideline: diagnosis, therapy and follow-up of melanoma. JDDG J der Dtsch Dermatologischen Gesellschaft. 2013;11:1–116. https://doi.org/10.1111/DDG.12113_SUPPL .
doi: 10.1111/DDG.12113_SUPPL
Hendel H, Lock-Andersen J, Dahlstrøm K, et al. Opfølgningsprogram for Modermærkekræft. Sundhedsstyrelsen 2015.; 2015. https://www.sst.dk/da/udgivelser/2015/~/media/06A4C4DB820A49F19311C5879672BE7D.ashx .
National Institute for Health and Care Excellence (NICE). Melanoma: Assessment and Management NICE Guideline, 2022. Retrieved 7 August 2022 at www.nice.org.uk/guidance/ng14 .
Helvind NM, Aros Mardones CA, Hölmich LR, et al. Routine PET-CT scans provide early and accurate recurrence detection in asymptomatic stage IIB–III melanoma patients. Eur J Surg Oncol. 2021;47:3020–7. https://doi.org/10.1016/j.ejso.2021.06.011 .
doi: 10.1016/j.ejso.2021.06.011
pubmed: 34120809
Turner RM, Dieng M, Khanna N, et al. Performance of long-term CT and PET/CT surveillance for detection of distant recurrence in patients with resected stage IIIA–D melanoma. Ann Surg Oncol. 2021;28:4561–9. https://doi.org/10.1245/S10434-020-09270-3/TABLES/3 .
doi: 10.1245/S10434-020-09270-3/TABLES/3
pubmed: 33393039
Dieng M, Lord SJ, Turner RM, et al. The impact of surveillance imaging frequency on the detection of distant disease for patients with resected stage III melanoma. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-021-11231-3 .
doi: 10.1245/s10434-021-11231-3
pubmed: 35142966
pmcid: 8990943
Ertekin SS, Podlipnik S, Riquelme-Mc Loughlin C, et al. Initial stage of cutaneous primary melanoma plays a key role in the pattern and timing of disease recurrence. Acta Derm Venereol. 2021. https://doi.org/10.2340/00015555-3832 .
doi: 10.2340/00015555-3832
pubmed: 34003298
pmcid: 9413807
Lee JW, Nam SB, Kim SJ. Role of 18F-fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography for the detection of recurrent disease after treatment of malignant melanoma. Oncology. 2019;97:286–93. https://doi.org/10.1159/000501398 .
doi: 10.1159/000501398
pubmed: 31437839
Danish Melanoma Group. Danish Melanoma Database Annual Report 2021 (Danish title: Dansk Melanom Database Årsrapport 2021). 2022:1–79.
Danish Melanoma Group. Dansk Melanom Database. National Årsrapport 2016. Annu Rep. 2016;(December):1–43. https://www.sundhed.dk/sundhedsfaglig/kvalitet/kliniske-kvalitetsdatabaser/kraeft/dansk-melanom-database/ .
Danish Melanoma Group. Dansk Melanom Database National Årsrapport 2017 Endelig Rapport.; 2017. www.melanoma.dk . Accessed March 9, 2020.
Hölmich LR, Klausen SSE, et al. The Danish melanoma database. Clin Epidemiol. 2016. https://doi.org/10.2147/CLEP.S99484 .
doi: 10.2147/CLEP.S99484
pubmed: 27822097
pmcid: 5094525
Bjerregaard B, Larsen OB. The Danish pathology register. Scand J Public Health. 2011;39(7 Suppl):72–4. https://doi.org/10.1177/1403494810393563 .
doi: 10.1177/1403494810393563
pubmed: 21775357
Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health. 2011;39(7 Suppl):30–3. https://doi.org/10.1177/1403494811401482 .
doi: 10.1177/1403494811401482
pubmed: 21775347
Pedersen CB. The Danish civil registration system. Scand J Public Health. 2011;39(7 Suppl):22–5. https://doi.org/10.1177/1403494810387965 .
doi: 10.1177/1403494810387965
pubmed: 21775345
Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health. 2011;39(7 Suppl):26–9. https://doi.org/10.1177/1403494811399958 .
doi: 10.1177/1403494811399958
pubmed: 21775346
Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–83.
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Aalen O. Statistics SJ-SJ of 1978 undefined: an empirical transition matrix for non-homogeneous Markov chains based on censored observations. JSTOR. Retrieved 25 May 2022 at https://www.jstor.org/stable/4615704 .
R Core Team. R Foundation for Statistical Computing. R: A language and environment for statistical computing. 2022. https://www.r-project.org/ .
Rueth NM, Xing Y, Chiang YJ, et al. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg. 2014;259:1215–22. https://doi.org/10.1097/SLA.0000000000000233 .
doi: 10.1097/SLA.0000000000000233
pubmed: 24096759
Bleicher J, Swords DS, Mali ME, et al. Recurrence patterns in patients with stage II melanoma: the evolving role of routine imaging for surveillance. J Surg Oncol. 2020;122:1770–7. https://doi.org/10.1002/jso.26214 .
doi: 10.1002/jso.26214
pubmed: 33098702
Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, Thompson JF. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol. 2007;14:1924–33. https://doi.org/10.1245/s10434-007-9347-2 .
doi: 10.1245/s10434-007-9347-2
pubmed: 17357855
Garbe C, Paul A, Kohler-Späth H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520–9. https://doi.org/10.1200/JCO.2003.01.091 .
doi: 10.1200/JCO.2003.01.091
pubmed: 12560444
Leiter U, Buettner PG, Eigentler TK, et al. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. J Am Acad Dermatol. 2012;66:37–45. https://doi.org/10.1016/j.jaad.2010.09.772 .
doi: 10.1016/j.jaad.2010.09.772
pubmed: 21700361
Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol. 2002;147:62–70. https://doi.org/10.1046/j.1365-2133.2002.04867.x .
doi: 10.1046/j.1365-2133.2002.04867.x
pubmed: 12100186
Leon-Ferre RA, Kottschade LA, Block MS, et al. Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. Melanoma Res. 2017;27:335–41. https://doi.org/10.1097/CMR.0000000000000344 .
doi: 10.1097/CMR.0000000000000344
pubmed: 28296712
Leeneman B, Franken MG, Coupé VMH, et al. Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. Eur J Surg Oncol. 2019;45:825–31. https://doi.org/10.1016/j.ejso.2019.01.225 .
doi: 10.1016/j.ejso.2019.01.225
pubmed: 30765270
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46. https://doi.org/10.1056/nejmoa1910836 .
doi: 10.1056/nejmoa1910836
pubmed: 31562797
Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626–36. https://doi.org/10.1056/NEJMoa1904059 .
doi: 10.1056/NEJMoa1904059
pubmed: 31166680
Nelson DW, Fischer TD, Graff-Baker AN, et al. Impact of effective systemic therapy on metastasectomy in stage IV melanoma: a matched-pair analysis. Ann Surg Oncol. 2019;26:4610–8. https://doi.org/10.1245/s10434-019-07487-5 .
doi: 10.1245/s10434-019-07487-5
pubmed: 31183639
Duffy AJ, Hogle NJ, LaPerle KM, Fowler DL. Comparison of two composite meshes using two fixation devices in a porcine laparoscopic ventral hernia repair model. Hernia. 2004;8:358–64. https://doi.org/10.1007/s10029-004-0258-x .
doi: 10.1007/s10029-004-0258-x
pubmed: 15290611
Naeser Y, Helgadottir H, Brandberg Y, et al. TRIM study protocol: a prospective randomized multicenter trial to assess the role of imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma. BMC Cancer. 2020. https://doi.org/10.1186/s12885-020-07632-4 .
doi: 10.1186/s12885-020-07632-4
pubmed: 33287744
pmcid: 7720485
Helvind NM, Hölmich LR, Smith S, et al. Incidence of in situ and invasive melanoma in Denmark from 1985 through 2012: a national database study of 24,059 melanoma cases. JAMA Dermatol. 2015;151:1087–95. https://doi.org/10.1001/jamadermatol.2015.1481 .
doi: 10.1001/jamadermatol.2015.1481
pubmed: 26061591
Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211–22. https://doi.org/10.1056/NEJMoa1613210 .
doi: 10.1056/NEJMoa1613210
pubmed: 28591523
pmcid: 5548388
Leiter U, Stadler R, Mauch C, et al. Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol. 2019;37:3000–8. https://doi.org/10.1200/JCO.18.02306 .
doi: 10.1200/JCO.18.02306
pubmed: 31557067
Gershenwald JE, Scolyer RA, Hess KR et al. Melanoma staging evidence based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; Doi: https://doi.org/10.3322/caac.21409